Xenova, Suntory Ltd. deal

The companies agreed to extend their drug discovery collaboration for a second time, to mid-1997. XNVAY will receive an undisclosed milestone payment for undertaking a program of synthetic chemistry based upon a Suntory lead compound.

The companies have been working since 1993 to discover and develop small molecule drugs to treat several immune-inflammatory diseases, with a focus on rheumatoid arthritis. ...